TY - JOUR
T1 - Drug-Eluting Stents in the Real World
T2 - How Intravascular Ultrasound Can Improve Clinical Outcome
AU - Moses, Jeffrey W.
AU - Dangas, George
AU - Mehran, Roxana
AU - Mintz, Gary S.
N1 - Funding Information:
The authors who contributed to this article have disclosed the following industry relationships. Jeffrey W. Moses, MD , serves as a consultant to Cordis/Johnson & Johnson, MIV Therapeutics, Caliber Therapeutics, and Svette Therapeutics. George Dangas, MD , is a member of the Speakers' Bureau of Abbott Laboratories, Boston, Scientific, Lilly, and sanofi-aventis. Roxana Mehran, MD , has received research/grant support to Cardiovascular Research Foundation (significant) from: Daiichi/Sankyo, Lilly; Medtronic Vascular; Abbott Vascular; The Medicines Company; Boston Scientific; sanofi-aventis; and has received honoraria/been a consultant to (Modest); Daiichi/Sankyo, Lilly; Medtronic Vascular; Abbott Vascular; The Medicines Company; sanofi-aventis. Gary S. Mintz, MD , has received fellowship salary support and is a member of the Speakers' Bureau of BostonScientific; and serves as a consultant for, and has equity in Volcano Corp; and serves as a consultant for LightLab and Terumo.
PY - 2008/11/3
Y1 - 2008/11/3
N2 - Although the benefits of drug-eluting stents for the treatment of native coronary lesions in patients undergoing percutaneous coronary interventions have been demonstrated in multiple clinical trials, there remains concern about the risk of late stent thrombosis. The MATRIX registry, a prospective study designed to reflect clinical conditions, has enrolled a varied population of complex patients who have received the sirolimus-eluting stent (SES) and long-term dual antiplatelet therapy. Contributing to the low rate of stent thrombosis and other complications after SES deployment in this study is the routine use of intravascular ultrasound (IVUS) imaging before and after implantation at a high rate (38%). Important technical considerations for the IVUS operator include stent expansion, residual edge stenosis, and malapposition. Ensuring adequate stent dimensions and wall contact can contribute to successful outcomes in patients receiving SES.
AB - Although the benefits of drug-eluting stents for the treatment of native coronary lesions in patients undergoing percutaneous coronary interventions have been demonstrated in multiple clinical trials, there remains concern about the risk of late stent thrombosis. The MATRIX registry, a prospective study designed to reflect clinical conditions, has enrolled a varied population of complex patients who have received the sirolimus-eluting stent (SES) and long-term dual antiplatelet therapy. Contributing to the low rate of stent thrombosis and other complications after SES deployment in this study is the routine use of intravascular ultrasound (IVUS) imaging before and after implantation at a high rate (38%). Important technical considerations for the IVUS operator include stent expansion, residual edge stenosis, and malapposition. Ensuring adequate stent dimensions and wall contact can contribute to successful outcomes in patients receiving SES.
UR - http://www.scopus.com/inward/record.url?scp=54549106998&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2008.09.006
DO - 10.1016/j.amjcard.2008.09.006
M3 - Article
C2 - 18928789
AN - SCOPUS:54549106998
SN - 0002-9149
VL - 102
SP - 24J-28J
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 9 SUPPL.
ER -